


SUPPLEMENTAL FIGURE 1: Quality control of ^{89}Zr -fresolimumab. Panel A shows a typical HPLC result of ^{89}Zr -fresolimumab with detection at 280 nm for the protein signal and co-registration of radioactive signal. Immunoreactivity of ^{89}Zr -fresolimumab was determined in a competitive binding assay with unlabeled fresolimumab. Competition curve (with 95% confidence interval) for the binding of ^{89}Zr -fresolimumab to TGF- β 3 is shown in B.



SUPPLEMENTAL FIGURE 2: Histological and immunohistochemical staining for hematoxylin and eosin (H&E) and phospho-Smad2 (pSmad2) on tumor and liver material from CHO xenograft mice.